Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Neurology

Long-Term Care and Maintenance Strategies

At a Glance

Long-term care for Balo concentric sclerosis is individualized because the condition may happen once or recur. Stable scans after an isolated attack may support observation with regular follow-up, while new lesions or relapses may prompt discussion of off-label medication.

Once the initial Balo’s Concentric Sclerosis (BCS) attack has passed, the focus shifts to the future. A common question for patients is whether they will need to take medication for the rest of their lives. Because BCS is so rare, there is no “one-size-fits-all” established treatment guideline. Instead, your neuroimmunologist will tailor a strategy based on your specific phenotype—the way the disease is behaving in your body [1][2].

Safety Warning: Do not stop or alter any prescribed long-term therapies without speaking with your neurology team, as doing so can trigger a rebound attack.

The “Watch and Wait” Strategy

It may come as a relief to learn that not everyone with BCS requires long-term medication. For many, BCS is monophasic, meaning it happens once and never returns [3].

Observation, or “watchful waiting,” is a shared decision that is often considered when:

  • The Attack was Isolated: You have only the concentric rings and no other “typical” Multiple Sclerosis (MS) spots on your MRI [1][4].
  • Stable Monitoring: Your follow-up MRIs show that the lesions are shrinking or scarring over, with no new areas of inflammation [1][5].

In these cases, the risk of side effects from long-term off-label drugs may outweigh the potential benefits. You will still need regular clinical check-ups and MRI scans to ensure the disease remains “quiet” [3][6]. Note that recovery after the first attack does not reliably predict your relapse risk, so staying engaged with your care team is vital.

When Maintenance Therapy is Considered

In other cases, BCS behaves more like a chronic condition, such as Multiple Sclerosis. Your doctor may consider a Disease-Modifying Therapy (DMT) if:

  • Recurrent Attacks: You experience a second neurological event (a “relapse”) [7][8].
  • New MRI Activity: Your scans show new or enlarging lesions, even if you don’t feel new symptoms [3][9].
  • MS Criteria: You have other lesions in different parts of your brain or spinal cord that meet the formal criteria for a diagnosis of Multiple Sclerosis [1][8]. If MS criteria are met, standard MS guidelines may inform the treatment.

Options for Long-Term Treatment

While there are no drugs approved specifically for BCS, doctors use medications that are highly effective in treating aggressive forms of MS.

B-Cell Depleting Therapies (Anti-CD20)

Currently, some specialists use anti-CD20 therapies, such as ocrelizumab and rituximab, for relapsing or MS-associated BCS [10][8]. These are infusions that target and remove specific B-cells in your immune system that drive inflammation.

  • Effectiveness: In a small, single-center study of 10 BCS patients treated with these therapies, all 10 remained free of relapses for a median of over five years [10]. While encouraging, this is very low certainty evidence and cannot establish comparative safety or superiority. Rituximab and ocrelizumab are used off-label in this context.
  • Major Risks: These therapies require Hepatitis B screening before starting, as they can cause viral reactivation. They also increase your risk for respiratory and systemic infections, can cause severe infusion reactions, and may lower your immunoglobulins (requiring monitoring) and alter vaccination timing.
  • MRI Impact: Individual cases have shown dramatic reductions in the size of “onion-skin” lesions after starting these treatments [11].

Other MS Medications

Other therapies like fingolimod or natalizumab are sometimes considered, but the evidence is mixed. While some patients do well, there have been rare reports of Balo-like lesions appearing shortly after starting or stopping these specific drugs [7][12].

Creating Your Maintenance Plan

The goal of maintenance therapy is to prevent “dissemination in time”—meaning we want to ensure no new damage happens next month or next year [1]. Whether you choose observation or off-label medication, your relationship with your neurologist will involve long-term surveillance. This typically includes:

  1. Scheduled MRIs: Scans to “map” any silent changes in the brain [3][6]. The schedule is determined by your specialist based on your specific case.
  2. Symptom Tracking: Keeping a log of any new numbness, weakness, or vision changes [13].
  3. Blood Work: If you are on a DMT, you will need regular tests to monitor your immune system health and watch for infection [10].

Common questions in this guide

Will I need BCS treatment for the rest of my life?
Not necessarily. BCS can be monophasic, meaning it happens once, and some people with an isolated attack and stable or improving MRI scans are monitored without long-term medication. Regular neurological visits and MRI scans are still important because recovery after the first attack does not reliably predict future relapse risk.
When would my doctor recommend long-term medication for BCS?
Long-term disease-modifying treatment may be considered after another neurological attack, new or enlarging MRI lesions, or findings that meet formal multiple sclerosis criteria. The choice depends on whether the disease appears isolated or relapsing and should be individualized by a neurologist or neuroimmunologist.
What medicines may be used for relapsing or MS-associated BCS?
No medication is approved specifically for BCS. Some specialists use anti-CD20 treatments such as ocrelizumab or rituximab off-label, meaning they are not specifically approved for BCS, while medicines such as fingolimod or natalizumab may be considered in selected cases. Evidence is limited and mixed.
What are the main risks of ocrelizumab or rituximab?
These treatments can increase infection risk, cause infusion reactions, lower antibody levels, and allow hepatitis B to reactivate. Before treatment, clinicians generally screen for hepatitis B and may monitor blood tests and vaccination timing during therapy.
How often will I need MRI scans after a BCS attack?
There is no single schedule for everyone with BCS. Your specialist sets the timing based on your symptoms, prior scans, and whether the lesions are shrinking or new areas of inflammation appear. MRI scans can help detect disease activity even when you feel well.
Can Balo concentric sclerosis come back after one attack?
It can be monophasic, meaning it does not return, but some people have further attacks or develop MRI findings consistent with a chronic condition such as multiple sclerosis. Improvement after the first attack cannot reliably show whether a relapse will occur, so continued clinical and MRI follow-up matters.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I meet the formal diagnostic criteria for Multiple Sclerosis, or is my condition currently considered 'isolated' BCS?
  2. 2.Based on my MRI, are there any other 'silent' lesions that might suggest a more chronic or relapsing course?
  3. 3.If we choose observation, how often will I need follow-up MRIs to ensure no new activity is occurring?
  4. 4.If we decide to start a DMT, why might you prefer a B-cell depleting therapy like ocrelizumab or rituximab over other MS medications?
  5. 5.Are there any specific risks for me with anti-CD20 therapies, such as my history of infections or my vaccination status?
  6. 6.What is our threshold for moving from observation to starting medication—one new lesion on MRI, or a new physical symptom?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Pseudotumoral demyelinating lesions: diagnostic approach and long-term outcome.

    Hardy TA

    Current opinion in neurology 2019; (32(3)):467-474 doi:10.1097/WCO.0000000000000683.

    PMID: 30844860
  2. 2

    Atypical inflammatory demyelinating syndromes of the CNS.

    Hardy TA, Reddel SW, Barnett MH, et al.

    The Lancet. Neurology 2016; (15(9)):967-981 doi:10.1016/S1474-4422(16)30043-6.

    PMID: 27478954
  3. 3

    Clinical and Radiologic Features, Pathology, and Treatment of Baló Concentric Sclerosis.

    Jolliffe EA, Guo Y, Hardy TA, et al.

    Neurology 2021; (97(4)):e414-e422 doi:10.1212/WNL.0000000000012230.

    PMID: 34011576
  4. 4

    From Baló's concentric sclerosis to multiple sclerosis: a series of 6 patients.

    Ayrignac X, Letourneau-Guillon L, Carra-Dallière C, et al.

    Multiple sclerosis and related disorders 2020; (42()):102078 doi:10.1016/j.msard.2020.102078.

    PMID: 32408148
  5. 5

    Baló's concentric sclerosis with spontaneous remission and favorable prognosis.

    Zhang YX, Fang GL, Tang JL, Lai QL

    Heliyon 2024; (10(12)):e33386 doi:10.1016/j.heliyon.2024.e33386.

    PMID: 39021993
  6. 6

    Advanced neuroimaging in Balo's concentric sclerosis: MRI, MRS, DTI, and ASL perfusion imaging over 1 year.

    Yeo CJJ, Hutton GJ, Fung SH

    Radiology case reports 2018; (13(5)):1030-1035 doi:10.1016/j.radcr.2018.04.010.

    PMID: 30228838
  7. 7

    Baló's concentric sclerosis - A rare entity within the spectrum of demyelinating diseases.

    Xie JS, Jeeva-Patel T, Margolin E

    Journal of the neurological sciences 2021; (428()):117570 doi:10.1016/j.jns.2021.117570.

    PMID: 34261000
  8. 8

    Heterogeneity of Baló's concentric sclerosis: a study of eight cases with different therapeutic concepts.

    Tzanetakos D, Vakrakou AG, Tzartos JS, et al.

    BMC neurology 2020; (20(1)):400 doi:10.1186/s12883-020-01971-2.

    PMID: 33138795
  9. 9

    Peripheral late reactivation of a previously typical monofocal Baló's concentric sclerosis lesion.

    Pique J, Bonneville F, Brassat D, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2015; (21(8)):1080-3 doi:10.1177/1352458515586087.

    PMID: 26014609
  10. 10

    Baló's concentric sclerosis: A retrospective case series.

    Peraza H, Rees J, Kresak J, et al.

    Multiple sclerosis and related disorders 2025; (103()):106712 doi:10.1016/j.msard.2025.106712.

    PMID: 40946697
  11. 11

    The effect of ocrelizumab on Balo's tumefactive lesion: A case report.

    Raghib MF, Bao F, Tessema S, et al.

    Radiology case reports 2024; (19(6)):2328-2331 doi:10.1016/j.radcr.2024.02.098.

    PMID: 38559660
  12. 12

    Fingolimod-associated Balo's concentric sclerosis in multiple sclerosis: A case report.

    Sharifi P, Moradi A, Moghadasi AN

    Clinical case reports 2024; (12(8)):e9266 doi:10.1002/ccr3.9266.

    PMID: 39109309
  13. 13

    Bridging the Gap: Baló Concentric Sclerosis-Like Leukoencephalopathy in Chronic Cocaine Use: A 1-Year Clinical and Imaging Follow-Up of 2 Cases.

    Lanzante M, Cerase A, de Mauro A, et al.

    Neurology 2026; (106(11)):e218068 doi:10.1212/WNL.0000000000218068.

    PMID: 42102330

This page is for informational purposes only and does not constitute medical advice. Decisions about MRI monitoring or off-label treatment, and any change to prescribed therapy, should be made with your neurologist or neuroimmunologist.

Get notified when new evidence is published on Baló concentric sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.